Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.
Unlike systemic chemotherapy for hematological malignancies with hepatitis B virus (HBV) infection, transarterial chemoembolization (TACE) for HBV-related hepatocellular carcinoma (HCC) has only recently been reported to cause HBV reactivation and subsequent hepatitis. Most patients with HBV-related HCC have an underlying disease with liver fibrosis or cirrhosis, and TACE may potentially induce HBV reactivation and liver decompensation. Currently, there are no clinical guidelines for managing TACE-caused HBV reactivation. In this review, we summarize the changes of HBV status and liver function after TACE and the effect of antiviral treatment before, during, or after TACE.
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.|State Key Laboratory of Southern China, Guangzhou, 510060, Guangdong, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
Xiao-Jun
XJ
Lin
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China. laoxming@mail.sysu.edu.cn.|State Key Laboratory of Southern China, Guangzhou, 510060, Guangdong, People's Republic of China. laoxming@mail.sysu.edu.cn.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China. laoxming@mail.sysu.edu.cn.
Xiang-Ming
XM
Lao
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.|State Key Laboratory of Southern China, Guangzhou, 510060, Guangdong, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
Ming
M
Shi
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.|State Key Laboratory of Southern China, Guangzhou, 510060, Guangdong, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
Sheng-Ping
SP
Li
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D004279:DNA, Viral / Q000097:blood*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects; D014775:Virus Activation
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D015251:Epirubicin; D000069283:Rituximab; D004317:Doxorubicin
Antiviral therapy; HBV reactivation; Hepatitis B virus; Hepatocellular carcinoma; Liver function; Nucleotide/nucleoside analogues; Transarterial chemoembolization